MOH
- Marketing authorisation holder: NOVO
- Status: likely_approved
Rivfloza (NEDOSIRAN) regulatory status in United Arab Emirates.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH has authorised it.
NOVO holds the UAE marketing authorisation.